Aurinia Pharmaceuticals Inc Dossier
Qualitative Analysis
Business overview
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) is a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative therapies for patients suffering from serious autoimmune diseases. The company's flagship commercial product is LUPKYNIS (voclosporin), the first FDA-approved oral therapy specifically indicated for the treatment of adult patients with active lupus nephritis (LN). LUPKYNIS has established a strong commercial footprint, supported by robust clinical data demonstrating a significant reduction in the risk of renal-related events or death. In addition to its commercial operations, Aurinia is advancing a clinical-stage pipeline, notably aritinercept (formerly AUR200), a novel biologic targeting BAFF and APRIL for the treatment of B-cell mediated and rare autoimmune diseases.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Focusing on increasing LUPKYNIS (voclosporin) adoption among lupus nephritis patients as an emerging standard-of-care treatment, supported by positive long-term renal outcomes data and international partnerships.
Expected impact: Drives the projected 2026 net product sales of $305 million to $315 million.
Advancing aritinercept, a highly potent dual BAFF/APRIL inhibitor, through clinical development. The company has initiated a clinical study in one autoimmune disease (including an integrated Phase I/II study in Generalized Myasthenia Gravis in Poland) and plans to initiate a study in a second autoimmune disease.
Expected impact: Establishes a highly differentiated, potentially best-in-class pipeline asset targeting B-cell mediated autoimmune diseases.
Streamlining the organizational structure through workforce reductions (including a 45% cut in late 2024) to focus resources on the commercial growth of LUPKYNIS and the development of aritinercept.
Expected impact: Realizes annualized cash-based operating expense savings of more than $40 million, significantly improving operating margins and cash flow generation.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To acquire Kezar's lead clinical asset, zetomipzomib, a first-in-class immunoproteasome inhibitor with multi-indication potential in autoimmune hepatitis, lupus nephritis, and systemic lupus erythematosus. The acquisition also brings Kezar's existing partnerships and cash reserves into Aurinia's portfolio.
Financial impact: Structured as $6.955 per share in cash plus one non-transferable contingent value right (CVR). The acquisition cost is significantly offset by Kezar's cash reserves (approximately $90.2 million as of Q3 2025), while the CVR structure mitigates upfront development risk.
Strategic Partnerships
Collaborating on the global development and commercialization of LUPKYNIS (voclosporin). Otsuka secured regulatory approval for LUPKYNIS in Japan in September 2024, expanding the drug's global footprint.
Terms: Triggered a $10 million milestone payment to Aurinia upon Japanese regulatory approval in late 2024, with ongoing royalty and license revenue (amounting to $4.1 million in Q1 2026).